UTHR · UNITED THERAPEUTICS Corp · Webcasts, Transcripts & Audio
$541.70
-29.68 (-5.19%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$20.39B
Shares
42.89M
Volume · Oct 2
1.24M
Avg daily vol (3M)
616.11K
UNITED THERAPEUTICS Corp Webcasts
Earnings calls, investor updates, investor days and conferences for UNITED THERAPEUTICS Corp (UTHR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲16%
$516.00M
$239.30M
'22 Q3
22-11-02
▲18.4%
$491.50M
$132.10M
'22 Q4
23-02-22
▲9.7%
$506.90M
$240.90M
'23 Q1
23-05-03
▲27.8%
$596.50M
$259.20M
'23 Q2
23-08-02
▲18.1%
$609.40M
$267.60M
'23 Q3
23-11-01
▲25.1%
$614.70M
$217.10M
'23 Q4
24-02-21
▲33.7%
$677.70M
$306.60M
'24 Q1
24-05-01
▲19.8%
$714.90M
$278.10M
'24 Q2
24-07-31
▲22.9%
$748.90M
$309.10M
'24 Q3
24-10-30
▲19.7%
$735.90M
$301.30M
'24 Q4
25-02-26
▲17.2%
$794.40M
$322.20M
'25 Q1
25-04-30
▲11.7%
$798.60M
$309.50M
'25 Q2
25-09-28
▲6.8%
$799.50M
$338.70M
'25 Q3
25-10-29
▲7.4%
$790.20M
$364.30M
'25 Q4
26-02-25
▼1.6%
$781.50M
$274.90M
'26 Q1
26-05-06
LATEST
▼1.9%
$783.30M
$333.00M
'26 Q2
26-08-05
Conference
Investor event
2026-09-08
UNITED THERAPEUTICS Corp (UTHR) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
UNITED THERAPEUTICS Corp (UTHR) Q2 2026 Earnings Call Transcript
Positive tone
Tyvaso nebulized IPF (Teton) franchise and label expansion
Quarterly revenue performance and commercial momentum
Sales force expansion ahead of new launches
Revenue
$783.30M
▼ 1.9% YoY Diluted EPS
$7.27
▲ 13.4% YoY Gross margin
87.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
UNITED THERAPEUTICS Corp (UTHR) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
UNITED THERAPEUTICS Corp (UTHR) Q1 2026 Earnings Call Transcript
Confident tone
Tyvaso/TETON for IPF
Ralinepag Phase III outcomes in PAH
New RALDPI inhaled product launch
Revenue
$781.50M
▼ 1.6% YoY Diluted EPS
$5.82
▼ 12.2% YoY Gross margin
82.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
UNITED THERAPEUTICS Corp (UTHR) Q4 2025 Earnings Call Transcript
Confident tone
Tyvaso for IPF (TETON program)
Tresmi soft mist inhaler
Ralinepag once-daily super prostacyclin
Revenue
$790.20M*
▲ 7.4% YoY Gross margin
86.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
UNITED THERAPEUTICS Corp (UTHR) January 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-10-29
UNITED THERAPEUTICS Corp (UTHR) Q3 2025 Earnings Call Transcript
Confident tone
TETON clinical program in pulmonary fibrosis
Tyvaso DPI franchise and competitive positioning
Business development and partnering interest
Revenue
$799.50M
▲ 6.8% YoY Diluted EPS
$7.16
▲ 12.1% YoY Gross margin
87.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-09-28
UNITED THERAPEUTICS Corp (UTHR) Q2 2025 Earnings Call Transcript
Confident tone
TETON IPF and PPF clinical program
Foundational commercial growth / Tyvaso franchise
Competitive threat from Liquidia / YUTREPIA (TPIP)
Revenue
$798.60M
▲ 11.7% YoY Diluted EPS
$6.41
▲ 9.6% YoY Gross margin
89.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
UNITED THERAPEUTICS Corp (UTHR) Q1 2025 Earnings Call Transcript
Confident tone
Treprostinil Product Franchise
Registration Studies and Regulatory Milestones
Record Quarterly Revenue Growth
Revenue
$794.40M
▲ 17.2% YoY Diluted EPS
$6.63
▲ 7.5% YoY Gross margin
88.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
UNITED THERAPEUTICS Corp (UTHR) Q4 2024 Earnings Call Transcript
Revenue
$735.90M*
▲ 19.7% YoY Gross margin
89.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2025-01-13
UNITED THERAPEUTICS Corp (UTHR) January 2025 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q3
2024-10-30
UNITED THERAPEUTICS Corp (UTHR) Q3 2024 Earnings Call Transcript
Confident tone
Record commercial revenue and product growth
Revolution wave – xenotransplantation and organ alternatives
Capital allocation – share repurchases and M&A
Revenue
$748.90M
▲ 22.9% YoY Diluted EPS
$6.39
▲ 18.8% YoY Gross margin
88.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
UNITED THERAPEUTICS Corp (UTHR) Q2 2024 Earnings Call Transcript
Confident tone
Foundational product confidence
Ralinepag PAH pipeline risk
Tyvaso franchise leadership
Revenue
$714.90M
▲ 19.8% YoY Diluted EPS
$5.85
▲ 11.6% YoY Gross margin
89.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
UNITED THERAPEUTICS Corp (UTHR) Q1 2024 Earnings Call Transcript
Confident tone
Ralinepag (OUTCOMES trial) in PAH
Xenotransplantation / organ manufacturing
Sotatercept competitive landscape
Revenue
$677.70M
▲ 33.7% YoY Diluted EPS
$6.17
▲ 27% YoY Gross margin
89.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
UNITED THERAPEUTICS Corp (UTHR) Q4 2023 Earnings Call Transcript
Confident tone
Tyvaso franchise and PH-ILD growth
TETON pulmonary fibrosis program
Manufactured organs and xenotransplantation
Revenue
$614.70M*
▲ 25.1% YoY Gross margin
88.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
UNITED THERAPEUTICS Corp (UTHR) Q3 2023 Earnings Call Transcript
Revenue
$609.40M
▲ 18.1% YoY Diluted EPS
$5.38
▲ 9.6% YoY Gross margin
88.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
UNITED THERAPEUTICS Corp (UTHR) Q2 2023 Earnings Call Transcript
Revenue
$596.50M
▲ 27.8% YoY Diluted EPS
$5.24
▲ 117.4% YoY Gross margin
89.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
UNITED THERAPEUTICS Corp (UTHR) Q1 2023 Earnings Call Transcript
Revenue
$506.90M
▲ 9.7% YoY Diluted EPS
$4.86
▼ 3.4% YoY Gross margin
89.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
UNITED THERAPEUTICS Corp (UTHR) Q4 2022 Earnings Call Transcript
Revenue
$491.50M*
▲ 18.4% YoY Gross margin
88.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
UNITED THERAPEUTICS Corp (UTHR) Q3 2022 Earnings Call Transcript
Revenue
$516.00M
▲ 16% YoY Diluted EPS
$4.91
▲ 43.6% YoY Gross margin
92.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
UNITED THERAPEUTICS Corp (UTHR) Q2 2022 Earnings Call Transcript
Revenue
$466.90M
▲ 4.6% YoY Diluted EPS
$2.41
▼ 34% YoY Gross margin
93.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
UNITED THERAPEUTICS Corp (UTHR) Q1 2022 Earnings Call Transcript
Revenue
$461.90M
▲ 21.8% YoY Diluted EPS
$5.03
▲ 724.6% YoY Gross margin
94.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
UNITED THERAPEUTICS Corp (UTHR) Q4 2021 Earnings Call Transcript
Revenue
$415.20M*
▲ 7.9% YoY Gross margin
91.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
UNITED THERAPEUTICS Corp (UTHR) Q3 2021 Earnings Call Transcript
Revenue
$444.70M
▲ 17% YoY Diluted EPS
$3.42
▼ 10.9% YoY Gross margin
93.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
UNITED THERAPEUTICS Corp (UTHR) Q2 2021 Earnings Call Transcript
Revenue
$446.50M
▲ 23.3% YoY Diluted EPS
$3.65
▲ 51.5% YoY Gross margin
91.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
UNITED THERAPEUTICS Corp (UTHR) Q1 2021 Earnings Call Transcript
Revenue
$379.10M
▲ 6.4% YoY Diluted EPS
$0.61
▼ 80.4% YoY Gross margin
93.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
UNITED THERAPEUTICS Corp (UTHR) Q4 2020 Earnings Call Transcript
Revenue
$384.90M*
▲ 23.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-28
UNITED THERAPEUTICS Corp (UTHR) Q3 2020 Earnings Call Transcript
Revenue
$380.10M
▼ 5.3% YoY Diluted EPS
$3.84
▲ 27.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-29
UNITED THERAPEUTICS Corp (UTHR) Q2 2020 Earnings Call Transcript
Revenue
$362.00M
▼ 3.1% YoY Diluted EPS
$2.41
▼ 48.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
UNITED THERAPEUTICS Corp (UTHR) Q1 2020 Earnings Call Transcript
Revenue
$356.30M
▼ 1.7% YoY Diluted EPS
$3.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
UNITED THERAPEUTICS Corp (UTHR) Q4 2019 Earnings Call
Revenue
$311.10M
▼ 18.4% YoY Diluted EPS
$1.20
▼ 18.9% YoY Gross margin
90.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 webcasts
Key facts
CIK
1082554
CUSIP
91307C102
13F (30d)
18 filings
14 filers
Visit website
Investor relations